Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 117.50 115.00 120.00 117.50 117.50 117.50 27,903 07:49:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 67

Reneuron Share Discussion Threads

Showing 8251 to 8274 of 8325 messages
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
359p price target from Allenby Capital
Not many follow rene, but it might be worth following it!
ReNeuron: refinanced and ready to riseThe biotech's recent fundraising and a good chart set-up have tempted Michael Taylor to take a position?April 21, 2021By Michael TaylorFor the second time this week, someone who has never been interested in trading or investing has asked me if they should buy a specific digital coin. Calling tops is a fool's errand. But it's safe to say the top is one day closer than it was yesterday. I've been reading Zero to One by Peter Thiel, in which the dotcom bubble is described as an 18-month frenzy. If we calculate the start of the latest bull run from April 2020, we would still have another six months of glorious speculative madness providing huge amounts of liquidity and volatility. But as we come closer and closer, the spikes go higher along with the risk. Still, we could be in for a fun summer.I have actively started moving capital into small-cap stocks that I believe have potential to weather the inevitable storm. These are uptrending and have strengthening fundamentals – stocks which I would like to add should any fast money exiting present any opportunities. Longer-term positions are now forming a part of my strategy in the stock market along with my active trading strategies that we look at in the column. I'll be posting some of these on Twitter and look forward to hearing any of your thoughts.RENE:LSEReNeuron Group PLC1mthToday change-1.29%Price (GBP)133.75One stock that I have been watching for a while is ReNeuron (RENE), a biotechnology company which researches and develops cell-based therapeutics. Drug companies can be high risk and high reward, but these risks can be mitigated depending on the company's cash position and needs, and where you enter the stock. Many UK biotech boards are poor at raising capital and end up destroying shareholder value after raising less than needed, with the idea of proving up value before raising more money later. This is a good idea in theory, but rarely works in practice. Delays are almost an inevitability and project schedules often shift (even if it is through no fault of the board).Take Phoenix Copper (PXC), which has taken the opposite approach. This is a junior mining company based in the USA, which recently raised money to finance the business with the goal of funding it through to production. The total placing shares were a whopping 73.9 percent of the existing shares – so the total number of shares in issue post placing was not far off double. It's a big dilution pill to stomach. But the advantage here is that it puts to bed any financing worries and secondly gives the board no excuses should they fail to reach production within this timeframe. While there will inevitably be the 10 per cent flippers from the placing, anyone buying now does not need to worry about a placing for the next 12 months, at least. I don't hold this stock, but it is an example of good management, in my view.ReNeuron decided to go to the market and raise £15 million last November. This gives them a runway of around 18 months – similarly ample time to get on with the job of creating value for shareholders without the worry and distraction of conducting That has not always been the case, as Chart 1 shows the stock trending sideways after a multi-year fall from 640p in 2015. I have marked with an arrow underneath a volume spike, which shows the stock rising on large volume. Perhaps this was a seller clearing and being transferred, or several trades being dealt on the back of positive news, however the stock burst through the pink 200-day exponential moving average (EMA) and formed a bull flag over the coming sessions.A bull flag is where the price consolidates sideways after a big rise, and so the rise candle is the mast, with the flag being formed in the consolidation. These are also known as pennants if the price volatility declines.We can see in Chart 1 that the stock retested the 200-day EMA resistance as support several times. This gave traders confidence that the stock was making a new trend, and I've marked the arrow when the stock broke out through this resistance. We can also see an increase of volume around this period, which was demand driving the price higher.Those that took this trade (sadly I didn't) will have made a nice multi-R gain if they had run the winner, as the stock surged 50 per cent before pausing for breath and resuming. You never know which trades will be your big winners, but by aiming to squeeze out as much juice as possible out of a trade you increase your chances of delivering high R payouts.?Moving across to Chart 2, I've marked the point with the top arrow the date where the company placed new equity at 70p. We can see in the prior months the stock selling off due to the knowledge that a placing was soon on the horizon – this is one advantage of a well-financed business, as there are no worries and therefore little stock price slippage due to people selling with the intention of reloading cheaper in the placing. The second arrow below shows the volume spike and increase in volume since that placing through the first quarter of 2021.I currently hold a position in ReNeuron, and I want to add to this should the stock break out of the 140p resistance zone. We can see a scruffy cup and handle forming on the chart which is my favourite pattern. I have no idea about the company's prospects, but the recent placing and chart combination gives me the confidence to take the trade. As with all non-profitable pharmaceutical companies it must come with a wealth warning, but for those looking to capture speculative upside in this sector I feel this could be a good entry point.Michael has started his Buy the Breakout newsletter which contains trading ideas and tips he has learned whilst trading. You can subscribe for free at his website here: @shiftingsharesNew subscribers to SharePad can claim a free month of data with the code: Michael Explore TopicsIdeasInvestment IdeasMore on Investment Ideas?April 22, 2021Big director share sales this week?April 22, 2021Macfarlane ticks the right boxes?April 22, 2021Intuitive Surgical: a cut above??April 22, 2021Ideas Farm: Infuriating intangiblesMore on Ideas?April 23, 2021Momentum investing stops working?April 22, 2021Big director share sales this week?April 22, 2021Macfarlane ticks the right boxes?April 22, 2021Intuitive Surgical: a cut above?FOLLOW US:Contact UsAbout UsHelpNearest Stockist
what does the recommendation state? any mention of suggest share price ?
Mention and recommendation in IC.
"Chart suggests a break of 150 will be followed by a rapid move up to 200+" I'm thinking more like 200 +++ long term.
small crow
SP reacting to LinkedIn post confirming Barcelona site opening
Chart suggests a break of 150 will be followed by a rapid move up to 200+.
I keep my tabs on this and the chart..could be ‘huge’
Next leg-up soon.
small crow
Lonely one-buy! Must be a signal....
small crow
Don't think the latest presentation has been shared here yet: Http:// Looking forwards to seeing more exosome deals while we wait for the hRPC data to arrive.
...and zho. ...and those who pushed it up on Friday, ignorant, I'm sure, that the article would appear over the weekend.
My thanks to Richard Griffiths and the Mail on Sunday.
Former City broker Richard Griffiths has been dubbed the ‘Welsh Wizard’ for his stock market bets, and has brought plenty of fellow investors under his spell. So market watchers take note. It has emerged that the Jersey dweller has taken a 7 per cent stake in ReNeuron. The small-cap is a stem cell research specialist which recently raised £15 million to expand a study of its treatment for a degenerative eye disease. The shares have rallied over the last month, up more than 30 per cent at £1.33. Griffiths’ followers will have their eyes trained on this one
Breakout to a new 50 day high on good volume. Looks primed for a move up.
Looking good for Monday. Another Holdings RNS maybe ??
There may not be much progress on the operating front but, at least, the share price is.
Are we looking at breakout at the end of one of those flag thingies? If so, my boots will be readied for filling.
small crow
Their schedule has slipped again. They have still only treated 3 people in the Ph2a extension. Could this go any slower!
ShareTalk with Olav today hxxps:// Shame nothing about exosome technology.
agreed its time for the rubber to hit the road
We sound like a solution looking for a problem all the time? - Seems to be a continuous dialogue to keep the funds flowing? - When do we set sail?
00:05 ReNeuron Group plc 07 May 2020 ReNeuron Group plc CTX cell line shows further potential ReNeuron's CTX cell line shows further potential Newly published positive efficacy data in an accepted model of Huntington's disease ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled "Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease". The new data show for the first time that ReNeuron's CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder. This study was led by Professor Jihwan Song from the Department of Biomedical Science at the CHA University in South Korea and the paper is accessible at the following link: [ ... ]
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 03:59:52